alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 9,476–9,500 of 10,985 studies · free to read (page 380 of 440) · 27,780 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,259 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Living well with dementia: a qualitative interview study on family caregivers’ call for more person- and family-centered dementia support

✓ Peer-reviewed alzhub usefulness score 38 out of 100. BMC Geriatrics 2025-10-06

Three themes were identified: (1) Struggling with conflicting emotions and social challenges - caregivers reported experiencing stress, physical exhaustion, and emotional strain due to constant availability and the challenges of managing behavioral changes, further intensified by isolation and shrinking social networks. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Beyond the Primary Caregiver: A Scoping Review of Family-Centered Dementia Caregiving Programs

✓ Peer-reviewed alzhub usefulness score 38 out of 100. American Journal of Alzheimer s Disease & Other Dementias® 2025-10-01

Most dementia caregiver programs focus on a single caregiver, overlooking diverse caregiving networks that include family, friends, and relatives who provide care. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Who Are Midlife Women Family Caregivers With Negative Attitudes Toward Alzheimer’s Disease and Dementia Care?

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Western Journal of Nursing Research 2025-02-06

Participants' attitude toward Alzheimer's disease and related dementia scores were significantly associated with employment status, race/ethnicity (Hispanic), and instrumental activities of daily living. 3 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Supporting Dementia Caregiving With a Mobile Care Ecosystem: Development and Mixed Methods Study

✓ Peer-reviewed alzhub usefulness score 38 out of 100. JMIR Aging 2025-11-03

In phase 1, the mean system usability scores increased from 65.4 (SD 11.8) in round 1 to 73.8 (SD 15.9) in round 3, exceeding the benchmark of 68. 5 key findings →

Design: clinical trial Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Epigenomics in Understanding Racial Disparities of Alzheimer’s Disease and Related Dementias

✓ Peer-reviewed alzhub usefulness score 38 out of 100. International Journal of Molecular Sciences 2026-01-11

Alzheimer's disease (AD) and related dementias (ADRD) are neurodegenerative conditions that cause gradual deterioration of cognition, memory and language in the elderly. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The potential impact of optimal blood pressure treatment intensity to reduce disparities in dementia between Black and White individuals

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of Alzheimer s Disease 2025-01-01

average annual dementia incidence in White, but not Black, adults (1% versus 0%), due to hypertensive individuals' greater survival, and reduce annual ASCVD events more in Black than White adults (13% versus 5%). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Global burden, spatiotemporal disparities, and sex-specific trends of early- and late-onset Alzheimer’s disease and other dementias: a comparative analysis and projections to 2035

✓ Peer-reviewed alzhub usefulness score 38 out of 100. BMC Neurology 2025-11-24

In 2021, LOAD demonstrated a substantially higher global burden than EOAD: incidence cases (8,455,150 [95% UI: 5,818,063-11,461,560] vs. 1,381,906 [894,768-1,963,453]), mortality cases (1,879,291 [471,472-4,968,222] vs. 73,386 [14,059-232,170]), and DALYs (32,558,570 [14,907,368-71,154,572] vs. 3,774,117 [1,696,439-8,881,154]). 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Projected Demographic Trends in the Likelihood of Having or Becoming a Dementia Family Caregiver in the U.S. Through 2060

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Populations 2025-05-20

This study predicts how sociodemographic trends-smaller family sizes, increased longevity, and marital patterns-could affect family care for people with dementia through 2060. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Spotlight on Alzheimer's disease and related dementias research in East Asia

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Alzheimer s & Dementia 2025-07-01

With a burgeoning dementia burden driven by unique demographic, genetic, and socioeconomic factors of East Asia, the region has made significant investments in understanding disease mechanisms, developing biomarkers, and exploring therapeutic approaches. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Early Alzheimer’s disease (mild cognitive impairment or mild dementia): Prevalence, diagnostics, treatment options, and guidelines in Asia, Australasia, and Pacific nations countries

✓ Peer-reviewed alzhub usefulness score 38 out of 100. The Journal of Prevention of Alzheimer s Disease 2025-08-30

Early diagnosis of mild cognitive impairment (MCI) and Alzheimer's disease (AD) with mild dementia is becoming increasingly important to enable patients to receive appropriate treatment with available amyloid-targeting therapies. 5 key findings →

Design: narrative review Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Integrative and interpretable framework to unveil the neurophysiological fingerprint of Alzheimer’s disease and mild cognitive impairment: A machine learning-SHAP approach

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of Applied Biomedicine 2025-06-13

Dementia and mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) are neurological pathologies associated with disruptions in brain electromagnetic activity, typically studied using magnetoencephalography (MEG) and electroencephalography (EEG). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

An Artificial Intelligence-Driven Multimorbidity Framework Reveals a Shared Metabolic and Immune Core Across Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Biomedicines 2026-02-16

Across AD, ALS, and FTD, a convergent multimorbidity architecture centered on a shared metabolic and immune core was identified, accompanied by prominent neurobehavioral processes and intermediate systems including gastrointestinal, endocrine, hematological, hepatic, and sensory pathways. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Mapping knowledge landscapes and emerging trends in digital biomarkers for dementia in older adults: A scoping and bibliometric analysis

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Archives of Gerontology and Geriatrics Plus 2025-04-09

This paper presents a systematic bibliometric analysis of the research landscape at the intersection of Alzheimer's disease and gerontechnology, identifying key contributors, research hotspots, and emerging trends. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Artificial intelligence in atrial fibrillation – Timely diagnosis, risk assessment and personalized management

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Indian Pacing and Electrophysiology Journal 2026-01-27

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia worldwide and is associated with substantial morbidity and mortality, including stroke, systemic embolism, heart failure, and dementia. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Alzheimer's and dementia: Diagnosis, assessment, and disease monitoring global, regional, and national burden of Alzheimer's disease and other dementias (ADODs) and their risk factors, 1990–2021: A systematic analysis for the Global Burden of Disease study 2021

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring 2025-04-01

Between 1990 and 2021, ADOD incidence, prevalence, deaths, and DALYs increased significantly. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed